Actually, suitable antigens for the development of anti-AML CAR-T cells, such as CD33 and CD123, are also commonly expressed on normal hematopoietic stem cells and myeloid progenitors as well as non-hematopoietic cells, thus predisposing them to on-target off-tumor adverse events, such as multilineage cytopenias [105,106]. This evidence concerns the gene CD33 and acute myeloid leukemia.